Change in Predicted 10-Year Cardiovascular Risk Following Roux-en-Y Gastric Bypass Surgery: Who Benefits?

Donadelli, Simara Paganini; Wilson, Steven E.; Marchini, Júlio Sérgio; Schmidt, André; Amato, Cristiana A.F.; Ceneviva, Reginaldo; Santos, José Ernesto dos; Nonino, Carla Barbosa

doi:10.1007/s11695-010-0348-z

Cited by 21 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to most studies, hypertension control appears to be so linked to improvement on insulin sensitivity and proinflammatory state as to proper weight loss (11,15,16,27) . Previous Brazilian reports have shown similar results (9,21) .…”

Section: Discussionsupporting

confidence: 79%

Control of Hypertension After Roux-en-Y Gastric Bypass Among Obese Diabetic Patients

Cazzo

Gestic

Machado

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Hypertension is a common disorder in general practice and has a widely known association with type 2 diabetes mellitus. Low adhesion to clinical treatment may lead to poor results. Obesity surgery can bring early and relevant resolution rates of both morbidities. Objective -To describe hypertension evolution after Roux-en-Y gastric bypass in patients with type 2 diabetes mellitus. Method -Descriptive observational study designed as a historical cohort of 90 subjects with hypertension and diabetes who underwent Roux-en-Y gastric bypass and were evaluated before and after surgery. Results -It was observed a hypertension resolution rate of 85.6% along with markedly decrease in anti-hypertensive usage. Mean resolution time was 3.2 months. Resolution was associated with homeostasis model assessment -insulin resistance, preoperative fasting insulin, anti-hypertensive usage, hypertension time, body mass index and percentage of weight loss. Resolution of hypertension was not statistically associated with diabetes remission within this sample. Conclusion -Roux-en-Y gastric bypass was a safe and effective therapeutic tool to achieve hypertension resolution in patients who also had diabetes mellitus.

show abstract

Section: Discussionsupporting

confidence: 79%

Control of Hypertension After Roux-en-Y Gastric Bypass Among Obese Diabetic Patients

Cazzo

Gestic

Machado

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Besides, it was observed that 43% of the studied patients made use of antihypertensive drugs before the surgery and, 2 years after the procedure, only 17% of those patients continued to use them 14. The use of cardiotonic medications decreased in 54% of patients, and of diuretics in 51% of patients, during this period.…”

Section: Main Drugs Studied In the Postoperative Period In Patients Wmentioning

confidence: 90%

The use of drugs in patients who have undergone bariatric surgery

Geraldo¹,

Fonseca

Gouveia³

et al. 2014

IJGM

View full text Add to dashboard Cite

According to the World Health Organization, obesity has become an epidemic in the 21st century affecting around 300 million people of all ages worldwide. Clinical treatment modalities for this disease are limited and ineffective when it comes to morbidly obese patients (body mass index – the weight in kilograms divided by height in meters squared – surpasses 40 kg/m2). Therefore, the alternative, surgical treatment, is the best option for these patients, namely gastric restrictive procedures or an intestinal bypass culminating in a malabsorptive syndrome. In the past 20 years, there has been a 70% increase in the number of bariatric procedures all over the world. The main pharmacokinetic consequence observed in the postoperative period of these individuals is a higher or lower absorption of orally administered drugs.

show abstract

“…It is yet to be determined whether the lipid alterations produced by bariatric procedures will reduce long-term CVD mortality. 275 Surgical treatments for adiposopathy RNYGB is the oldest procedure that is known to cause weight loss and metabolic changes by restricting gastric size and rerouting the gut. Gastric bypass involves creation of a small (20-30 mL) stomach pouch located at the distal end of the esophagus, which is sometimes surgically divided from the rest of the stomach.…”

Section: The Impact Of Bariatric Surgery and Weight Loss On Lipidsmentioning

confidence: 99%

“…An area that requires further study is whether these lipid, glucose, and inflammatory markers continue to show positive changes in the long-term and whether this correlates to reduced CV risk. Donadelli et al 275 looked at lipid alterations at 2 years post-RNYGB and calculated Framingham Risk based on the metabolic parameters present at that time. Forty-two patients were included in the study.…”

Section: Administrationmentioning

confidence: 99%

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Bays

Tóth

Kris-Etherton

et al. 2013

Journal of Clinical Lipidology

399

280

View full text Add to dashboard Cite

The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

show abstract

Change in Predicted 10-Year Cardiovascular Risk Following Roux-en-Y Gastric Bypass Surgery: Who Benefits?

Abstract: Weight loss secondary to surgery was sustained after 2 years and promoted improvement of comorbidities, with an important reduction of 10-year cardiovascular risk especially among patients with previous risk factors.

Cited by 21 publications

References 30 publications

Control of Hypertension After Roux-en-Y Gastric Bypass Among Obese Diabetic Patients

Control of Hypertension After Roux-en-Y Gastric Bypass Among Obese Diabetic Patients

The use of drugs in patients who have undergone bariatric surgery

Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Contact Info

Product

Resources

About